UNASSIGNED: 7026 Background: SS1P is an immunotoxin targeting @entity36705 , a @entity5 antigen highly expressed in @entity3620 ( @entity3620 ). Preclinical studies showed marked synergy between SS1P and chemotherapy, leading to this frontline trial in pleural @entity3620 . METHODS: @entity1 with no prior treatment, advanced disease, ECOG 0-2, and good organ function received pemetrexed 500 mg/m(2) and @entity900 75 mg/m(2) every 3 weeks for 6 cycles. SS1P dose escalation was: 25   g/kg; 35   g/kg; 45   g/kg and 55   g/kg on days 1, 3 and 5 of cycles 1 and 2. CT scans were performed every 2 cycles. RESULTS: Nineteen @entity1 (16 males, 3 females) have been treated, with median age of 68 y (51 to 78 y). One @entity1 at 55   g/kg had Grade 3 @entity1295 , considered dose-limiting. The maximum tolerated dose (MTD) of SS1P with chemotherapy was 45   g/kg. Adverse events possibly or probably related to SS1P included Grade 3 @entity4988 (n=6), @entity158 (n=3), and @entity551 (n=2); and Grade 2 @entity4988 (n=11), @entity1295 (n=9), @entity4 (n=6), @entity551 (n=5), and @entity158 (n=5). One @entity1 died from @entity1398 during cycle 1. Of the 14 evaluable @entity1 treated at all dose levels, 7 had partial response (PR), 3 @entity66 ( @entity66 ) and 4 @entity74 ( @entity74 ). Of 7 @entity1 treated at MTD, 5 had PR, 1 @entity66 and 1 @entity74 . Of the 10 patients whose serum @entity36705 levels were evaluated before and at completion of treatment all 5 @entity1 with PR had significant decrease in serum @entity36705 (63-83%). Two of 3 @entity1 with @entity74 had increased @entity36705 levels (16%-34%), while 1 pt had a slight decrease (7%). Two @entity1 with @entity66 had discordant responses (17% increase and 60% decrease). CONCLUSIONS: SS1P with pemetrexed and @entity900 is well tolerated and results in significant anti- @entity5 activity with 5 PRs, and 1 @entity66 among the 7 @entity1 treated at MTD. Serum @entity36705 responses correlate with the radiological response with all @entity1 who obtained a PR having significant decrease in serum @entity36705 levels.

Antitumor activity of SS1P with pemetrexed and XXXX for front-line treatment of pleural mesothelioma and utility of serum @entity36705 as a marker of @entity5 response.

@entity1 :: ('9606', 'Species') :: ['Patients', 'patients', 'patient'] @entity66 :: ('MESH:D004194', 'Disease') :: ['stable disease', 'SD'] @entity4988 :: ('MESH:D034141', 'Disease') :: ['hypoalbuminemia'] @entity5 :: ('MESH:D009369', 'Disease') :: ['tumor'] @entity4 :: ('MESH:D004487', 'Disease') :: ['edema'] @entity900 :: ('MESH:D002945', 'Chemical') :: ['cisplatin'] @entity1295 :: ('MESH:D005221', 'Disease') :: ['fatigue'] @entity551 :: ('MESH:D007022', 'Disease') :: ['hypotension'] @entity3620 :: ('MESH:C562839', 'Disease') :: ['malignant mesothelioma', 'MM'] @entity1398 :: ('MESH:D009503', 'Disease') :: ['neutropenic sepsis'] @entity74 :: ('MESH:D030342', 'Disease') :: ['PD', 'progressive disease'] @entity158 :: ('MESH:D010146', 'Disease') :: ['pain'] @entity36705 :: ('10232', 'Gene') :: ['mesothelin']
@entity900 :: (MESH:D002945,Chemical) :: ['cisplatin']
